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AbstrACt 
Objectives To analyse treatment outcomes and share 
clinical data from a large, single-centre, well-curated 
database (8174 eyes/6664 patients with 120 756 single 
entries) of patients with neovascular age-related macular 
degeneration (AMD) treated with anti-vascular endothelial 
growth factor (VEGF). By making our depersonalised raw 
data openly available, we aim to stimulate further research 
in AMD, as well as set a precedent for future work in this 
area.
setting Retrospective, comparative, non-randomised 
electronic medical record (EMR) database cohort study 
of the UK Moorfields AMD database with data extracted 
between 2008 and 2018.
Participants Including one eye per patient, 3357 
eyes/patients (61% female). Extraction criteria were 
≥1 ranibizumab or aflibercept injection, entry of ‘AMD’ in 
the diagnosis field of the EMR and a minimum of 1 year 
of follow-up. Exclusion criteria were unknown date of first 
injection and treatment outside of routine clinical care 
at Moorfields before the first recorded injection in the 
database.
Main outcome measures Primary outcome measure was 
change in VA at 1 and 2 years from baseline as measured 
in Early Treatment Diabetic Retinopathy Study letters. 
Secondary outcomes were the number of injections and 
predictive factors for VA gain.
results Mean VA gain at 1 year and 2 years were +5.5 
(95% CI 5.0 to 6.0) and +4.9 (95% CI 4.2 to 5.6) letters, 
respectively. Fifty-four per cent of eyes gained ≥5 letters 
at 2 years, 63% had stable VA (±≤14 letters), 44% of eyes 
maintained good VA (≥70 letters). Patients received a mean 
of 7.7 (95% CI 7.6 to 7.8) injections during year 1 and 13.0 
(95% CI 12.8 to 13.2) injections over 2 years. Younger age, 
lower baseline VA and more injections were associated 
with higher VA gain at 2 years.
Conclusion This study benchmarks high quality EMR 
study results of real life AMD treatment and promotes open 
science in clinical AMD research by making the underlying 
data publicly available.
IntrOduCtIOn
The treatment of neovascular age-related 
macular degeneration (AMD) has been revo-
lutionised by the development of anti-vas-
cular endothelial growth factor (VEGF) 
agents such as ranibizumab and afliber-
cept.1–4 Unfortunately, real world results from 
retrospective studies are typically inferior to 
those from randomised controlled trials 
(RCTs), with fewer administered injections 
and significant intercountry and intercentre 
differences in therapy administration and 
outcomes.5–9 Although retrospective studies 
and audits may be more likely than RCTs to 
reflect results in clinical practice, they still are 
not truly representative of outcomes in real 
world populations.5–7 10 11 Major drawbacks of 
retrospective study designs are small sample 
sizes with selection bias and suboptimal 
methods for handling of both missing data 
and losses to follow-up (LTFU).11 12 Survival 
bias in particular can lead to skewed results: 
omission of cases LTFU from the analysis 
leads to selection of a non-random cohort 
with potential overestimation of visual acuity 
(VA) gains through exclusion of patients that 
stop treatment early due to irreversible visual 
loss such as foveal scarring or other adverse 
effects.12 
strengths and limitations of this study
 ► Large sample size, retrospective, single centre, 
electronic medical record database study
 ► High-quality real life data
 ► Open science approach with sharing of deperson-
alised raw data
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The advent of electronic medical records (EMR) has 
facilitated the collection of large amounts of data in 
routine clinical practice and thus has the potential to 
make retrospective study populations more representa-
tive of real life.13–18 This is very much dependent, however, 
on the quality of data entry and the reliable follow-up of 
patients, and so these issues can remain problematic. The 
amount of data available from EMR systems also chal-
lenges the traditional methods of validation, analytics 
and reporting, and there is a struggle to implement the 
existing clinical research guidelines.12 19–21 For example, 
in 2015, the RECORD statement highlighted the chal-
lenges of using routinely collected observational health 
data.21 A further problem is the variation of data collec-
tion in the different EMR registers in different hospitals 
and countries. The International Consortium for Health 
Outcomes Measurement (ICHOM) AMD working group 
has also proposed a standard set of clinical characteris-
tics, interventions and outcomes including preferential 
methods of VA recording (logarithm of the minimum 
angle of resolution or Early Treatment Diabetic Retinop-
athy Study (ETDRS) letters).22
At Moorfields Eye Hospital, an EMR was initiated in 
October 2008, and its successor, OpenEyes, was imple-
mented in September 2012. Subsequently, data from 
both systems were merged into the current centralised 
repository, the data warehouse. We have created a data set 
from this which represents, to our knowledge, the largest 
single-centre cohort of patients receiving treatment for 
neovascular AMD in the world. This Moorfields AMD 
data set is increasing steadily, with 909 new patients in 
2017 alone, a number typically only comparable in magni-
tude to multicentre studies.14 16 Apart from its sheer size, 
key advantages of this data set include the ability to clean 
and validate data directly, the completeness due to the 
mandatory input of relevant fields including VA, the 
consistency of VA measurements in ETDRS letters, the 
lack of requirement to merge data from different sites 
and systems, the standardised treatment scheme following 
national guidelines, and the ability to directly access the 
raw imaging data from each study visit.
The aim of this study is to analyse 1-year and 2-year 
VA outcomes, determine predictive factors of VA gain in 
treatment-naive eyes from the Moorfields AMD database 
and to aid in scientific progress by making the deperson-
alised raw data from our study openly available to the 
research community.21 23
MethOds
data collection
Data for this retrospective, comparative, non-randomised 
cohort study were extracted from the data warehouse, the 
centralised storage for all EMR data, of Moorfields Eye 
Hospital. Data were extracted between 21 October 2008 
and 8 August 2018. Extraction criteria were ≥1 ranibi-
zumab or aflibercept injection, entry of ‘AMD’ in the 
diagnosis field of the EMR and a minimum of 1 year of 
follow-up. Exclusion criteria were unknown date of first 
injection, any treatment outside of routine clinical care 
at Moorfields before the first recorded injection in the 
database, including pegaptanib, previous laser or photo-
dynamic therapy, and bevacizumab. The rationale for 
exclusion of bevacizumab is that in the National Health 
Service (NHS), neovascular AMD is generally treated with 
the licensed therapeutics ranibizumab or aflibercept, and 
not with the off-label bevacizumab.24 25 The date of the first 
injection was defined as the baseline date. The data set 
has been depersonalised for publication and approval for 
data collection and analysis was obtained from the Institu-
tional Review Board at Moorfields (ROAD17/031). The 
study adhered to the tenets set forth in the Declaration 
of Helsinki.
Outcome measures
The primary outcomes were mean change in VA from 
baseline as measured in ETDRS letters, proportion of eyes 
gaining ≥5 letters, proportion of eyes with stable vision 
(change in VA<15 letters to baseline), proportion of eyes 
with good vision (≥20/40 or 70 letters), and proportion 
of eyes with poor vision (≤20/200 or 35 letters) at base-
line, year one, and year two. Those endpoints have been 
used in the pivotal trials and/or have been included in 
the ICHOM reporting recommendations.1–4 22 Secondary 
outcomes included the number of injections, and effect 
of baseline characteristics and injection numbers on 
changes in VA. Definitions for 1 year and 2 year outcome 
dates were taken from previous real-world studies as visits 
closest to 52 weeks and 104 weeks post baseline date 
within ±8 weeks.6 13 We used the STROBE cohort checklist 
when writing our report.20
efforts to minimise bias
Clinical information from patients with neovascular AMD 
is manually entered to the Moorfields Eye Hospital EMR 
(OpenEyes) at each visit. The EMR requires mandatory 
completion for a number of fields at each patient visit, 
including VA, central retinal thickness, treatment deci-
sion, treatment drug and injection number, thus mini-
mising the number of missing data entries. Of all 120 756 
single entries, missing/zero visual acuity measurements 
were encountered in 4059 (4.1%) of all entries. After 
manual cleaning of all 4059 missing entries, missing data 
accounted for 808 (0.9%) entries. Patients aged <55 or 
>100 and eyes with injection numbers ≥50 were manu-
ally checked. Description of manual cleaning including 
a CONSORT diagram is shown in supplementary mate-
rial (see online supplementary 1, sFigure 1). Visual 
acuities below measurable ETDRS letters were converted 
to logMAR 2.0/–15 letters, logMAR 2.3/–30 letters and 
logMAR 2.7/–50 letters for count fingers, hand move-
ments and light perception, respectively.26 To avoid 
bias due to intereye correlation, statistical analysis was 
restricted to one eye per patient, that is, the first eye of 
a patient if sequentially treated, and a randomly selected 
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eye if simultaneously treated. Outcomes of second-treated 
fellow eyes will be reported separately.
statistical analysis
The data were analysed using the statistics software R 
(https://www. r- project. org/; provided in the public 
domain by R Core team 2017 R Foundation for Statis-
tical Computing, Vienna, Austria). The ggplot2 package 
was used for plots. The eye was defined as unit of anal-
ysis. Descriptive statistics included mean +/-95% CI and 
median, where appropriate. Differences between groups 
were evaluated using Mann Whitney U test and Pearson 
chi-square. Multivariate linear regression analysis was 
performed to assess relationship of predictive factors 
and VA change. Independent variables used included 
gender, baseline age, baseline VA and injection number. 
VA change at 1 and 2 years following initiation of treat-
ment were each interrogated as the dependent variable. 
A p value <0.05 was considered significant.
Patient and public involvement
Patients and public were not involved in the study as this 
was a retrospective cohort study.
data sharing statement
Data available from the Dryad Digital Repository: https:// 
doi. org/ 10. 5061/ dryad. 97r9289
results
Patient demographics
The full data set consisted of 8174 treatment-naïve 
eyes/6664 patients with 1 20 756 single entries treated 
for neovascular AMD in the Moorfields database 
between 21 October 2008 and 9 August 2018.
The data set for analysis consisted of 3357 eyes/patients 
(61% female). Mean age was 78 (95% CI 77.7 to 78.3) 
years at baseline. Mean VA was 56.2 (95% CI 55.6 to 56.8) 
letters. Of these, 1105 eyes (33%) were treated with ranibi-
zumab, 1533 (46%) with aflibercept, and 719 eyes (21%) 
were treated with both ranibizumab and aflibercept. The 
starting year of treatment ranged between 2007 and 2018. 
Therapeutic choices at Moorfields Eye Hospital changed 
after 2013 and both ranibizumab and aflibercept were 
offered as alternative first-line agents. After this change, 
a number of patients were switched from one agent to 
another resulting in over 50% of eyes in the full dataset 
receiving both drugs during the course of treatment. 
Baseline characteristics are shown in table 1.
Of the 1162 patients not completing the 2-year 
follow-up date, 254 patients had died. LTFU occurred in 
27% of eyes for 2 year follow-up. To address the poten-
tially resulting survival bias of, 1 year outcomes for the 
cohort not completing 2-year follow-up and the cohort 
completing the 2-year follow-up are shown.
Visual outcomes at 1 and 2 years
Mean VA gain at 1 and 2 years were +5.5 (95% CI 5.0 to 
6.0) and +4.9 (95% CI 4.2 to 5.6) letters, respectively. The T
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mean number of injections over the first year and first 
2 years were 7.7 (95% CI 7.6 to 7.8) and 13.0 (95% CI 12.8 to 
13.2), respectively (figure 1). Percentages of eyes gaining 
vision (change in VA ≥5 letters), stable vision (change 
in VA <15 letters), good vision (VA ≥70 letters/>20/40), 
and poor vision (VA ≤35 letters/≤20/200) are shown in 
table 1 and figure 2.
Comparison of subgroups that did not complete the 
2-year follow-up and the cohort that did complete the 
2-year follow-up showed a significantly lower mean base-
line VA for those with a follow-up of less than 2 years (54.4 
vs 57.9 letters, p<0.05) a lower mean gain of letters (4.1 vs 
6.8 letters, p<0.05) as well as a lower injection frequency 
(7.5 vs 8.0, p<0.05) at 1 year.
determinants of change in VA at 1 and 2 years
Age at presentation, VA at presentation, and injec-
tion number have each been shown independently to 
correlate with VA outcomes eyes with neovascular AMD 
receiving anti-VEGF therapy.12 We therefore wanted to 
assess whether these parameters would correlate with 1- 
and 2 year VA outcomes in our cohort.
We carried out multiple linear regression analyses 
of the clinical variables (gender, baseline age, baseline 
VA, injection number) with VA change at 1 year (online 
supplementary 2, sTable 1) and 2 years (online supple-
mentary 2, sTable 2) following baseline as dependent vari-
ables. Regression models were statistically significant and 
suggest that a lower baseline VA, lower baseline age and 
higher injection number are independently associated 
with a higher VA change at year one and two. Indeed, 
this is the trend demonstrated when VA change over the 
observation period is stratified by baseline age and VA 
(figure 3).
Figure 1 Visual acuity (A&C) and change in visual acuity (B&D) over time for all eyes and stratified by follow-up period (black: 
1-year completers only; grey: 2-year completers). Bars represent 95% CI.  
Figure 2 Percentage of eyes with good VA (≥70 letters), intermediate VA (36–69 letters), and poor VA (≤35 letters) at different 
follow-up times (A) and comparison of cohorts of different follow-up times at 1 year (B). VA - visual acuity.
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dIsCussIOn
In this study, we show that patients treated with ranibi-
zumab and/or aflibercept for neovascular AMD at 
Moorfields Eye Hospital achieve good visual outcomes, 
particularly those patients who present at an earlier age 
with better visual acuity, and who subsequently receive 
frequent intravitreal injections.
The Moorfields AMD Database is a large, consistent, 
and clean dataset of neovascular AMD treatment and 
visual outcomes, perhaps the largest single-centre dataset 
of its kind worldwide. We have made this freely available 
to download with this manuscript in an effort to benefit 
the AMD research community. At a minimum, this will 
allow for use of alternative statistical approaches and facil-
itate research reproducibility. 21 We also hope it will allow 
for the testing of new hypotheses and thus provide new 
insights into the treatment of this condition.27 We have 
also developed systems so that the Moorfields AMD Data-
base is automatically updated over time, with minimal 
need for manual cleaning of data. Just under 1000 new 
cases of neovascular AMD present to Moorfields Eye 
Hospital on a yearly basis - this may be particularly useful 
as new therapeutics for AMD continue to be introduced. 
Additionally, we plan on releasing data for long-term 
follow-up of these (5 years and beyond), as well as their 
associated raw imaging data (colour fundus photography 
and optical coherence tomography (OCT) in every eye at 
every visit).
At one and 2 years, our results of mean VA gains confirm 
the existing evidence in real-life studies, for example, the 
Fight Retinal Blindness (FRB) group in Australia/New 
Zealand for ranibizumab/aflibercept with nearly iden-
tical baseline characteristics and visual acuity outcomes 
for mixed ranibizumab/aflibercept treatment (see online 
supplementary 3, sTable 3).10 28
However, VA gains reported by the Writing Committee 
for the UK Age-Related Macular Degeneration EMR Users 
Group are considerably poorer which likely is explained 
by the reported capacity constraints resulting in reduced 
treatment frequency of with a mean of 9.4 injections 
over 2 years versus over 13 in our cohort and the FRB.16 
VA results from randomised prospective studies (eg, the 
Comparison of Age-related macular degeneration Treat-
ment Trials (CATT) and Vascular endothelial growth 
factor Trap-Eye: Investigation of Efficacy and Safety in 
Wet AMD study (VIEW)) have been shown to be superior 
to retrospective real-life data.1 4
This is also reflected in our data and is explained by the 
broader inclusion criteria, and the less strict treatment 
regimens with fewer administered injections. Comparison 
of cohorts that completed only 1 year of follow-up versus 2 
or more years showed that eyes with shorter follow-up 
were older, had lower baseline VA, gained fewer letters 
at the 1 year follow-up, and received fewer injections over 
the first year. The loss to follow-up reflects the real-life 
setting of the study where patients transfer to stable AMD 
clinics, their vision has deteriorated and rendered further 
treatment unreasonable, or they are not able to further 
attend clinics. We deliberately did not perform any impu-
tational replacement of missing data, but clearly describe 
the baseline characteristics and compare the 1-year results 
of the cohort LTFU before 2 years.12
VA gain over time is dependent on baseline charac-
teristics and injection frequency.12 14 29 Increasing age 
diminishes the VA gain expected as does a higher base-
line acuity due to ceiling effect.30 Baseline VA could even 
Figure 3 Change in visual acuity stratified by baseline VA (A), baseline age (B) and injection number at 2 years (C). Bars 
represent 95% CI.
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emerge as a surrogate measure for accessibility to treat-
ment and quality of care, since simply looking at VA gains 
would underestimate centres that achieve short time from 
diagnosis to first treatment resulting in above average 
baseline VA but ceiling effect on VA gains.8 12 16 Injection 
frequency has been recognised as another significant 
factor influencing VA gain and has been hypothesised 
to be the major factor in studies comparing ranibizumab 
and aflibercept due to the change in posology from treat-
ment as needed to treat-and-extend concomitant with the 
change from ranibizumab to aflibercept in clinical prac-
tice.14 29 31 32.
The retrospective nature and EMR-based data collection 
of our study introduce several limiting factors. Smoking 
status of our patients was not consistently available and 
thus, could not be included in the prediction model. 
Smoking has been identified as a risk factor for the devel-
opment of neovascular AMD, but might also impact treat-
ment response.33 There is invariably survival bias within 
the data, as LTFU cannot be assumed to occur at random. 
However, baseline characteristics of LTFU as well as differ-
ences in outcomes for 1- and 2-year follow-up cohorts 
have been clearly described to address this. To date, there 
is no systematic collection of patient-reported outcome 
measures (mobility and independence, emotional well-
being, as well as reading and accessing information 
questionnaires) as suggested by ICHOM.22 EMR studies 
introduce new challenges to medical research: Data 
quality issues, hidden in large datasets, could lead to 
false interpretation, i.e. ‘garbage in – garbage out’, lack 
of computer science skills may limit reproducibility of 
research results, and sharing of medical data poses legal 
issues.12 20 21 34 Our study addresses this with a transparent, 
STROBE statement conforming structure, and an open 
science approach with information governance approved 
depersonalised data sharing.
The main advantages of this study are the quality and 
amount of data coming from one single centre and one 
database. Moorfields Eye Hospital has a standardised treat-
ment protocol for neovascular AMD, formerly treatment 
as needed, and fixed-first year/treat-and extend regimen 
with the introduction of aflibercept in 2014 (flow chart 
for aflibercept use is shown in online supplementary 4, 
sFigure 2). The extensive manual cleaning and the homo-
geneous standards of data input (VA in ETDRS letters, 
mandatory fields) have formed a highly reliable resource 
which will be enhanced in the future with an automated 
update and validation to allow for continued growth and 
quality improvement of clinical AMD data.
In conclusion, this study shows that with a diligent 
approach, analysis of well maintained EMR data can lead 
to high quality real-life results and electronic availability 
of data facilitates maximisation of its potential in sharing 
research resources with the community, ultimately with 
the goal of improving patient care in real-life. In the near 
future, we plan to report on long-term visual outcomes 
(eg, after 5 years), anatomic outcomes, and fellow-eye 
involvement, as well as the differential therapeutic effects 
of ranibizumab and aflibercept. In each case, we plan to 
release the raw data that underpins these reports - we hope 
that this will help promote an open-science approach to 
the study of neovascular AMD, and thus to direct patient 
benefit in the longer term.
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